Oral contraceptives and heavy periods

Affiliations

Editorial

James O Drife. Obstet Gynecol. 2011 Apr.

. 2011 Apr;117(4):773-774.

doi: 10.1097/AOG.0b013e318212b333.

¹ James O. Drife, MD, is from the University of Leeds School of Medicine, Leeds, United Kingdom; e-mail: j.o.drife@leeds.ac.uk.

No abstract available

Comment on

Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.
Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Jensen JT, et al. Obstet Gynecol. 2011 Apr;117(4):777-787. doi: 10.1097/AOG.0b013e3182118ac3. Obstet Gynecol. 2011. PMID: 21422847 Clinical Trial.

1. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl E2 for treating dysfunctional uterine bleeding. Obstet Gynecol 2000;96:913–20.
1. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. National Center for Health Statistics. Vital Health Stat 23. 2010;29:1–44.
1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,357 women with ovarian cancer and 78,303 controls. Lancet 2008;371:303–14.
1. Kaunitz AM. Hormonal contraception in women of older reproductive age. N Engl J Med 2008;358:1262–70.
1. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with E2 valerate and dienogest: a randomized study. Obstet Gynecol 2011;117:777–87.